Januvia diabetes drug, molecular model. Januvia (sitagliptin) is a hypoglycaemic drug, one that reduces blood sugar levels. Diabetes is a condition in which blood sugar levels can get dangerously high due to a lack of insulin, the hormone that reduces them. Januvia works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP- 4). DPP-4 rapidly deactivates the incretin hormone GLP-1 (glucagon-like peptide 1), which promotes insulin release. Hence, inhibiting DPP-4 prolongs the effects of GLP-1, keeping insulin levels high. Atoms are colour-coded: carbon (grey), hydrogen (yellow), oxygen (red), nitrogen (blue) and fluorine (green). Januvia is marketed by Merck, and was approved in the USA in October 2006.
Model release not required. Property release not required.